The estimated Net Worth of Howard Clowes is at least $29 Mille dollars as of 8 May 2024. Mr. Clowes owns over 9,804 units of Plus Therapeutics stock worth over $29,021 and over the last 4 years he sold PSTV stock worth over $0. In addition, he makes $0 as Independent Director at Plus Therapeutics.
Howard has made over 6 trades of the Plus Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 9,804 units of PSTV stock worth $20,000 on 8 May 2024.
The largest trade he's ever made was buying 15,000 units of Plus Therapeutics stock on 2 June 2022 worth over $8,550. On average, Howard trades about 3,830 units every 116 days since 2020. As of 8 May 2024 he still owns at least 21,497 units of Plus Therapeutics stock.
You can see the complete history of Mr. Clowes stock trades at the bottom of the page.
Howard Clowes has been appointed as Independent Director of the Company effective 4/1/2020. Mr. Clowes served for nearly four decades as a partner at DLA Piper, a leading law firm, where Mr. Clowes served in leadership positions in the firm’s Corporate and Securities Practice, advising public and private companies on securities law, financing, Mergers and Acquisition and general corporate matters. Mr. Clowes has a J.D. from the University of California, Berkeley (where he now serves as a Lecturer), and a BA from the University of California, Santa Barbara.
Howard's mailing address filed with the SEC is C/O PLUS THERAPEUTICS INC., 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN, TX, 78756.
Over the last 5 years, insiders at Plus Therapeutics have traded over $4,518 worth of Plus Therapeutics stock and bought 251,584 units worth $410,360 . The most active insiders traders include Greg Petersen, Marc H Hedrick e Richard J Hawkins. On average, Plus Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $8,201. The most recent stock trade was executed by Marc H Hedrick on 10 September 2024, trading 8,000 units of PSTV stock currently worth $9,840.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Plus Therapeutics executives and other stock owners filed with the SEC include: